Primary Record
ozagrel
- In stock
- 6,803 g
- Purity
- 99.7 %
- CAS
- 82571-53-7
Compound Identifiers & Properties
- CAS
- 82571-53-7
- PubChem CID
- 5282440
- SMILES
- C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
- Canonical SMILES
- O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1
Names & Synonyms
- ozagrel
- 82571-53-7
- Ozagrelum
- pulmoza
- Ozagrel [INN]
- Cataclot
- Domenan
- Ozagrelum [Latin]
- Xanbon
- Ozagrel free acid
- Ozagrel sodium
- Sodium ozagrel
- ozagrel hydrochloride
- Cataclot (TN)
- Ozagrel (INN)
- OZAGREL HCl
- OKY-046
- Ozagrel, OKY-046
- KCT-0809
- OZAGREL [MI]
- OKY 046
- OZAGREL [MART.]
- Prestwick2_000979
- Prestwick3_000979
- RefChem:169192
- OZAGREL [WHO-DD]
- CHEMBL11662
- D0C7AA
- D0T2IH
- UNII-L256JB984D
- AC1NR02S
- SCHEMBL4210
- OKY046
- C13H12N2O2
- L256JB984D
- Ozagrel hydrochloride hydrate
- MFCD00868231
- BSPBio_001017
- DTXSID6048547
- BPBio1_001119
- CHEMBL542549
- GTPL9866
- orb1300951
- ZINC5389
- 82571-53-7 (free base)
- 4-(1-imidazoylmethyl)cinnamic acid
- DTXCID6028103
- CHEBI:92359
- CHEBI:134938
- SHZKQBHERIJWAO-AATRIKPKSA-N
- HMS2089O14
- HMS3649M21
- HMS3884N21
- HMS5081E13
- (E)-p-(Imidazol-1-ylmethyl)cinnamic acid
- BCP12147
- EX-A5744
- HY-B0428
- Ozagrel (ophthalmic, eye disorders)
- BDBM50017896
- GSK610677
- s2496
- (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
- AKOS015889403
- C13-H12-N2-O2
- AC-2080
- ACN-048761
- CCG-266782
- CID5282440
- CS-2534
- DB12017
- (E)-3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)ACRYLIC ACID
- NCGC00025195-02
- (E)-4-(1-Imidazolylmethyl)cinnamic Acid
- AJ-08246
- AN-14330
- AS-71327
- BC209190
- H981
- J34.702G
- LS-14195
- SC-22625
- SY102886
- (E)-4-(imidazol-1-ylmethyl)cinnamic acid
- SBI-0207081.P001
- AB0013402
- AB2000601
- LS-177692
- TL8005457
- 2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (2E)-
- A4344
- AB00514722
- FT-0630908
- NS00068113
- SW197369-5
- J2.539.247G
- 3-(4-Imidazol-1-ylmethyl-phenyl)-acrylic acid
- A10688
- D08327
- M05738
- AB00514722-10
- AB00514722-12
- AB00514722-13
- AB00514722_14
- AB00514722_15
- 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-2-propenoic acid
- 4-(1H-Imidazole-1-ylmethyl)benzenepropenoic acid
- 571O537
- A840374
- SR-01000597793
- (2E)-3-{4-[(1H-imidazol-1-yl)methyl]phenyl}prop-2-enoic acid
- (E)-3-(4-Imidazol-1-ylmethyl-phenyl)-acrylic acid
- 2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, (E)-
- 3-[4-(1-imidazolylmethyl)phenyl]-2-propenoic acid
- I01-1859
- Ozagrel (ophthalmic, eye disorders), Kissei/ Teika
- Q7116436
- SR-01000597793-8
- (E)-3-[4-[(1-Imidazolyl)methyl]phenyl]acrylic Acid
- 3-(4-(imidazol-1-ylmethyl)phenyl)prop-2-enoic acid
- 3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
- BRD-K19525698-003-01-1
- BRD-K53061490-001-02-6
- BRD-K53061490-003-03-0
- BRD-K53061490-003-13-9
- BRD-K53061490-003-14-7
- Ozagrel(OKY-046) Thromboxane A2 synthetase inhibitor
- (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic acid
- (E)-3-[p-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid
- 3-[4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2E-PROPENOIC ACID
- (2E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
- (E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]propenoic acid
- (E)-3-[4-[(1H-Imidazol-1-yl)methyl]phenyl]acrylic Acid
- 3-{4-[(1H-Imidazol-1-yl)methyl]phenyl}prop-2-enoic acid
- (E)-3-[4-(1H-Imidiazol-1-ylmethyl)phenyl]-2-propenic acid
- (E)-3-[P-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2-PROPENO
- (2E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)prop-2-enoic acid
- (2E)-3-[4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]ACRYLIC ACID
- (E)-3-[P-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2-PROPENOIC ACID
- 130952-46-4
- 888-092-6